OAB medication list: Free PDF template

An OAB medication list puts every drug used for overactive bladder in one place. Each entry carries the class, the dose range, and the safety flag that decides who should get it. Seven anticholinergics and two beta-3 agonists make up the nine agents in routine US use.

The age flag is the line that matters most. Oxybutynin immediate release is the one agent the American Geriatrics Society tells practices to avoid in older adults. It is still widely prescribed anyway.

Below you will find the full reference table, dose ceilings and renal adjustments, plus a routine for working the list into prescribing.

Key takeaways

Two drug classes cover overactive bladder, seven anticholinergics and two beta-3 agonists.

Six anticholinergics carry an FDA indication for overactive bladder, while flavoxate is approved for urinary symptoms of lower tract inflammation.

Oxybutynin immediate release tops out at 20 mg a day, taken as 5 mg four times daily.

Beers Criteria flag oxybutynin immediate release in older adults, so trospium or a beta-3 agonist is the safer opening choice.

Beta-3 agonists skip dry mouth and constipation, but mirabegron lifts blood pressure and inhibits CYP2D6.

What overactive bladder is, and when drug therapy starts

Overactive bladder is a symptom syndrome, not a diagnosis you confirm on a test. It means urinary urgency, with or without urge incontinence.

Frequency of eight or more voids in 24 hours and at least one void a night usually come with it. The detrusor contracts during filling, so the urge arrives before the bladder is full.

Drugs are second-line. Bladder training, timed voiding, fluid adjustment and pelvic floor work are first-line in the AUA and SUFU guidelines. Pharmacotherapy starts when those measures have had a fair run and urgency still breaks up the day.

Both drug classes do the same job by different routes. Anticholinergics block muscarinic receptors so the detrusor stops contracting when it should be filling. Beta-3 agonists switch on β3 receptors and relax the muscle instead. Efficacy is broadly comparable, so tolerability and contraindications usually decide the choice.

Every FDA-approved agent in one table

The table below is the master reference. It lists nine agents across two classes, with the dose range, the available formulations and the one fact that most often changes the prescription.

Flavoxate sits slightly apart from the rest. Its FDA indication covers urinary symptoms caused by lower urinary tract inflammation, not overactive bladder itself. Treat it as an adjacent option rather than a first choice.

Anticholinergics block the bladder’s urgency signal

Anticholinergics block M3 muscarinic receptors on the detrusor, which stops the involuntary contractions that create urgency. They carry most OAB prescriptions in the US, and six of them hold an FDA indication for the condition.

Flavoxate is the seventh agent in this group, though its approval covers a narrower set of symptoms. What separates them is receptor selectivity, how much crosses into the brain, and which formulations exist.

• Oxybutynin (Ditropan): 10-20 mg/day as divided IR doses, or 5-30 mg/day ER. Sold as a tablet, a patch and a gel. Highest central penetration of the class.
• Tolterodine (Detrol): 2-4 mg/day. An M2 and M3 antagonist with fewer central effects than oxybutynin.
• Solifenacin (VESIcare): 5-10 mg once daily. M3-selective, and the antimuscarinic most often paired with mirabegron in trials.
• Darifenacin (Enablex): 7.5-15 mg once daily as an ER tablet. M3-selective, with a 7.5 mg cap alongside a strong CYP3A4 inhibitor.
• Fesoterodine (Toviaz): 4-8 mg once daily. A prodrug of tolterodine’s active metabolite, so titration is gentle.
• Trospium (Sanctura): 20 mg twice daily, or 60 mg once daily as ER. Hydrophilic, so very little reaches the brain. That makes it the anticholinergic of choice in older adults.
• Flavoxate (Urispas): 100-200 mg three or four times daily. A urinary antispasmodic with anticholinergic activity, approved for symptoms of lower urinary tract inflammation rather than OAB.

Beta-3 agonists work without drying the patient out

Beta-3 agonists take the other route. They switch on β3-adrenergic receptors on the detrusor, which relaxes the muscle during filling. Dry mouth, constipation and cognitive effects largely drop away. Blood pressure takes their place as the thing to watch. Two agents are approved.

• Mirabegron (Myrbetriq): 25-50 mg once daily, approved in 2012. In OAB trials, mean blood pressure rose roughly 0.5 to 1 mmHg above placebo. Healthy-volunteer studies at 50 mg reached about 3.5/1.5 mmHg. It is not recommended once systolic pressure reaches 180 mmHg. It also inhibits CYP2D6, which lifts levels of tricyclic antidepressants and some antiarrhythmics.
• Vibegron (Gemtesa): 75 mg once daily as a fixed dose, approved in 2020. Minimal CYP interaction, and no blood-pressure signal in the trial program. That makes it the easier choice on a crowded medication list.

Record a blood pressure before the first prescription, then again at review. A shared vital signs record keeps both readings in one place. The comparison is then in front of you at review, not scattered across two notes.

How to choose between the two classes

Efficacy rarely settles it. Head to head, urgency reduction is similar across the classes. The decision comes down to what the patient cannot tolerate and what they already take.

Six findings in the history do most of the work, and taking them in a fixed order beats weighing them all at once.

The table below carries the same decisions with the reasoning attached. That is the version worth keeping next to the prescribing screen.

Side effects decide whether a patient stays on therapy

Most OAB prescriptions stop for tolerability, not for lack of effect. Knowing which complaint belongs to which class lets you counsel up front and manage it before the patient quits.

What anticholinergics cause

• Dry mouth: 40 to 60 percent of patients, and worst with oxybutynin IR. Sugar-free gum, frequent sips and a saliva substitute usually hold it.
• Constipation: 10 to 30 percent, because the same receptor blockade slows the gut.
• Blurred vision: caused by pupil dilation. Warn patients who do a lot of close work.
• Cognitive effects: confusion and memory trouble in older adults, mostly with oxybutynin IR, through central M1 blockade.
• Tachycardia: uncommon, and less likely with the M3-selective agents.

What beta-3 agonists cause

• Raised blood pressure: mirabegron only. Check at baseline, then again four to eight weeks after starting.
• Headache: the commonest complaint at around 5 percent, usually mild and short-lived.
• Rhinitis: reported in under 2 percent.
• Tachycardia: under 1 percent of patients.

Adherence is worth tracking as carefully as the dose. Ask the patient to keep a medication log between visits. You then arrive at the review knowing whether a poor response is the drug or the schedule.

Older adults need a different first choice

In adults 65 and over, start with trospium or a beta-3 agonist. Altered pharmacokinetics, more comorbidities and greater sensitivity to anticholinergic load all push the same way. The American Geriatrics Society Beers Criteria name oxybutynin immediate release as the agent to avoid, citing confusion and delirium risk.

Where each agent lands on the Beers list

Avoid: oxybutynin immediate release. Central anticholinergic effects raise confusion and delirium risk, and the evidence behind the recommendation is strong. Flavoxate carries the same warning.

Use with caution: the extended-release forms and the M3-selective agents. Central exposure is lower, though it does not disappear. Trospium and the beta-3 agonists stay the preferred starting point.

Renal function then sets the ceiling. Mirabegron drops to 25 mg a day once eGFR falls between 15 and 29, and vibegron is not recommended below that. Anticholinergics clear mostly through the liver, but the effects a frail patient feels most, constipation and incomplete emptying, get worse with age.

Book the review at four to eight weeks either way. That is long enough to judge response and short enough to catch a tolerability problem before the patient stops on their own.

Starting doses, ceilings and renal adjustments

Use this table once the prescription is being written and the questions turn numerical. It gives the starting dose, the ceiling and the adjustment that applies when kidney or liver function is reduced.

One figure trips people up more than any other. Oxybutynin immediate release is often quoted with a 15 mg ceiling. The label allows 5 mg four times daily, which is 20 mg.

When oral therapy stops working, what comes next

Two escalation routes matter once oral agents have failed or proved intolerable. Intradetrusor onabotulinumtoxinA is FDA-approved for refractory OAB and is given cystoscopically, usually by a urologist. Desmopressin is narrower, reserved for nocturia, and it carries a hyponatremia risk that rules out casual use.

Sacral neuromodulation and percutaneous tibial nerve stimulation sit alongside them as device options. Both need a referral. The practical job at this stage is a clean handover, naming what was tried, at what dose, for how long, and why it stopped.

Putting the list to work in your prescribing routine

A reference only earns its keep once it sits inside the workflow. It also works best when the data behind it is already in the system. Good prescription management keeps doses, formulations and repeat dates in one record, so nobody rebuilds the picture from a printed sheet.

A five-step routine for the consult

1. Screen before you prescribe. Run the five checks above against the history, covering glaucoma, cognition, bowel habit, blood pressure and current medications.
2. Pick the class, then the agent. Contraindications choose the class. Cost, formulation and formulary rules usually choose the agent within it.
3. Write the rationale down. One line naming why this agent and not another is what protects the decision at the next audit or handover.
4. Set expectations. Tell the patient it takes four to eight weeks to judge, and which side effect to expect first.
5. Book the review before they leave. Four to eight weeks, with a blood pressure recheck if you started a beta-3 agonist.

Most of that screening can happen before the patient sits down. Comorbidities, current medications and prior treatment failures all arrive with paperless patient intake. The consult then starts from a complete history rather than a blank page.

Common mistakes worth avoiding

• Prescribing oxybutynin IR to a patient over 65 because it is the cheapest option on the formulary.
• Starting mirabegron with no baseline blood pressure, which leaves nothing to compare at review.
• Switching class after two weeks, before the first agent has had a fair trial.
• Missing a second anticholinergic already on the list, so the total burden doubles unnoticed.
• Titrating trospium IR upward. Its starting dose is already the ceiling.

How Pabau keeps prescribing decisions on the patient record

Most practices run this list on paper. The reference sits in a drawer or a shared folder. The rationale goes into free text, if it goes anywhere at all. The review depends on somebody remembering to book it.

Practice management software like Pabau closes those loops in one record. Digital intake forms collect the comorbidities and current medications before the appointment, so the contraindication screen is half done by the time the patient arrives. The chosen agent, the dose and the reason then sit on the patient record, not in a separate note.

Automated recalls handle the four-to-eight-week review, so the reassessment is booked at the point of prescribing rather than chased later. Pabau Scribe, our AI scribe, drafts the consultation note while you talk, which gets the prescribing rationale written down while it is fresh.

Every subscription includes those features, so a solo prescriber gets the same recall engine and the same forms as a multi-site group.

Keep every prescribing decision on the record

Pabau collects medication history at intake, stores the reason behind each prescription on the patient record, and books the four-to-eight-week review automatically. Your team stops rebuilding the picture from paper.

Book a demo

Conclusion

Two classes and nine agents sound like a lot of choice, but one screen narrows it fast. The contraindications pick the class. Cost, formulation and coverage then pick the agent inside it.

The reference itself is the easy part. Keeping the reasoning attached to the patient, and the review actually booked, is what separates a list that gets used from one that gets printed.

Download the reference, work the five checks into the consult, and book the review before the patient leaves. Book a demo to see how Pabau keeps the medication decision, the rationale and the recall on one patient record.

Continue your research

Recording what the patient actually takes? The medication log template gives you a dated record of doses and missed days between appointments.

Handing the patient a schedule? The medication schedule template lays out timing across the day, which helps when a drug is taken four times daily.

Building reference cards for the team? The drug card template holds the class, the action and the monitoring points for one agent on a single page.

Tracking blood pressure on a beta-3 agonist? The vital signs record keeps the baseline and the review reading side by side.

Documenting a reaction that stops therapy? The adverse reaction form captures the agent, the reaction and the action taken in one place.

Frequently asked questions